OSLO, Nov. 16, 2018 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treatsolid tumors, today announces that CMO Magnus Jäderberg will present at the NeoAg Summit 2018 (formerly Neoantigen Summit) in Boston
NeoAg Summit 2018Date: 16 November 2018 Presenter:
Title: TG01, a neo-antigen specific vaccine targeting RAS mutations in solid tumours
Presentation slides will be available on www.targovax.com/Investors.
For further information, please contact:Renate Birkeli, Investor RelationsPhone: +47-922-61-624Email: firstname.lastname@example.org Media and IR enquires:Andreas Tinglum - Corporate Communications (Norway)Phone: +47-9300-1773Email: email@example.com Simon Conway/Stephanie Cuthbert - FTI Consulting (International)Phone: +44-20-3727-1000Email: Targovax@fticonsulting.com
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/targovax-to-present-at-neoag-summit-2018-300751943.html
Subscribe to our Free Newsletters!